• Leveraging whole tumor cells as antigen-presenting tools to stimulate immune responses effectively

• Combining shared tumor-associated antigens and patient-specific neoantigens in a single vaccine format to broaden immune coverage and overcome tumor heterogeneity

• Presenting preclinical data on TME remodelling and immune activation in ovarian cancer models to validate mechanism and guide clinical translation

• Enhancing immune potency with rational adjuvant selection and delivery strategy to improve response durability and therapeutic efficacy